Vidazolibo-B (09887.HK): The first patient in the phase Ib/II trial of Opadezumab single antibody for melanoma was successfully treated.

Smart Finance APP News, Vlietzi Bu-B (09887.HK) announced that the first patient in the phase Ib/II clinical trial (NCT07099430) evaluating the use of Opalutsumab (PD-L1/4-1BB bispecific antibody LBL-024) alone or in combination with other drugs for first-line treatment of advanced melanoma has successfully received treatment.